Connect your AI

Collegium Pharmaceutical, Inc. COLL Price / book

Price / book at other companies

Catalyst PharmaceuticalCPRX

3×-0.7×

Avanos MedicalAVNS

0.8×0.0×

Pacira BioSciences, Inc.PCRX

1.4×0.0×

Supernus PharmaceuticalsSUPN

2.8×+1.0×

Theravance BiopharmaTBPH

2.9×+0.2×

Rhythm Pharmaceuticals, Inc.RYTM

48.3×-128×

Other financials

Income statement

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

Market cap$1.15B+20.4%

Enterprise value$869.67M+2.5%

P/E15.4×-6.4×

P/S1.5×0.0×

Profitability

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Calculated from Collegium Pharmaceutical, Inc.’s reported figures.

market cap/total stockholders equity=3.4×

Based on the most recent quarter.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s price / book?: Collegium Pharmaceutical, Inc. (COLL) reported price / book of 3.4× in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s price / book changed year-over-year?: Collegium Pharmaceutical, Inc.'s price / book decreased by 17.8% year-over-year, from 4.1× to 3.4×.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s price / book?: Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s price / book has grown at a 5.4% compound annual growth rate (CAGR), from 3.7× to 4.9×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.